UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A

Oncogene, 2014-05, Vol.33 (21), p.2790-2800

2014

Volltextzugriff (PDF)

TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort

Oncogene, 2007-07, Vol.26 (31), p.4596-4599

2007

Volltextzugriff (PDF)

A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel

Annals of oncology, 2016-03, Vol.27 (3), p.454-460

2016

Volltextzugriff (PDF)

Phase II study of sunitinib in men with advanced prostate cancer

Annals of oncology, 2009-05, Vol.20 (5), p.913-920

2009

Volltextzugriff (PDF)

Role of diet in prostate cancer: the epigenetic link

Oncogene, 2015-09, Vol.34 (36), p.4683-4691

2015

Volltextzugriff (PDF)

Validation of metastasis-free survival as a surrogate endpoint for overall survival in localized prostate cancer in the era of docetaxel for castration-resistant prostate cancer

Annals of oncology, 2024-03, Vol.35 (3), p.285-292

2024

Volltextzugriff (PDF)

Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 Study

Journal of clinical oncology, 1999-08, Vol.17 (8), p.2506-2513

1999

Volltextzugriff (PDF)

Impact of symptomatic skeletal events on health-care resource utilization and quality of life among patients with castration-resistant prostate cancer and bone metastases

Prostate cancer and prostatic diseases, 2017-09, Vol.20 (3), p.276-282

2017

Volltextzugriff (PDF)

Autoantibody Signatures in Prostate Cancer

The New England journal of medicine, 2005-09, Vol.353 (12), p.1224-1235

2005

Volltextzugriff (PDF)

Pharmacokinetic (PK) analysis of concurrent administration of enzalutamide (enza) and crizotinib (crizo) in patients with metastatic castration resistant prostate cancer (CRPC)

Annals of oncology, 2018-10, Vol.29, p.viii298-viii298

2018

Volltextzugriff (PDF)

Gene expression correlates of clinical prostate cancer behavior

Cancer cell, 2002-03, Vol.1 (2), p.203-209

2002

Volltextzugriff (PDF)

Patient-Reported Impotence and Incontinence After Nerve-Sparing Radical Prostatectomy

JNCI : Journal of the National Cancer Institute, 1997-08, Vol.89 (15), p.1117-1123

1997

Volltextzugriff (PDF)

Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer

Annals of oncology, 2012-05, Vol.23 (5), p.1234-1240

2012

Volltextzugriff (PDF)

Imaging, procedural and clinical variables associated with tumor yield on bone biopsy in metastatic castration-resistant prostate cancer

Prostate cancer and prostatic diseases, 2014-12, Vol.17 (4), p.325-331

2014

Volltextzugriff (PDF)

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

The New England journal of medicine, 2015-11, Vol.373 (19), p.1814-1823

2015

Volltextzugriff (PDF)

Outcomes of prechemotherapy (pCRx) abiraterone acetate (AA) or enzalutamide (E) for metastatic castration-resistant prostate cancer (mCRPC) after ADT + Docetaxel (D) or ADT alone for metastatic hormone sensitive prostate cancer (mHSPC) in a multi-institution hospital-based registry

Annals of oncology, 2017-09, Vol.28, p.v278-v279

2017

Volltextzugriff (PDF)

Predictors of duration of abiraterone acetate in men with castration-resistant prostate cancer

Prostate cancer and prostatic diseases, 2016-12, Vol.19 (4), p.398-405

2016

Volltextzugriff (PDF)

Recent progress in management of advanced prostate cancer

Oncology (Williston Park, N.Y.), 2005-04, Vol.19 (5), p.631-636

Kantoff, Philip

2005

Volltextzugriff (PDF)

Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T

Prostate cancer and prostatic diseases, 2014-09, Vol.17 (3), p.259-264

2014

Volltextzugriff (PDF)

Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet

Annals of oncology, 2018-01, Vol.29 (1), p.23-25

2018

Volltextzugriff (PDF)

Prostate Intraepithelial Neoplasia Induced by Prostate Restricted Akt Activation: The MPAKT Model

Proceedings of the National Academy of Sciences - PNAS, 2003-06, Vol.100 (13), p.7841-7846

2003

Volltextzugriff (PDF)

Patient-reported symptoms after primary therapy for early prostate cancer: results of a prospective cohort study

Journal of clinical oncology, 1998-01, Vol.16 (1), p.275-283

1998

Volltextzugriff (PDF)

Imaging yield from 133 consecutive patients with prostate cancer and low trigger PSA from a single institution

Clinical radiology, 2016-03, Vol.71 (3), p.e143-e149

2016

Volltextzugriff (PDF)

Percent Positive Biopsy Cores and the Risk of Death from Prostate Cancer in Men Treated with Radiation and Androgen Deprivation Therapy

International journal of radiation oncology, biology, physics, 2014-09, Vol.90 (1), p.S155-S155

2014

Volltextzugriff (PDF)

Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer

Urology (Ridgewood, N.J.), 1999-09, Vol.54 (3), p.523-527

1999

Volltextzugriff (PDF)

1 – 25 von 440

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(430)
Mit Volltextzugriff
(371)

Publikationsform

Artikel
(421)
Tagungsberichte
(19)

Sprache

Englisch
(439)
Japanisch
(38)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A

TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort

A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel

Phase II study of sunitinib in men with advanced prostate cancer

Role of diet in prostate cancer: the epigenetic link

Validation of metastasis-free survival as a surrogate endpoint for overall survival in localized prostate cancer in the era of docetaxel for castration-resistant prostate cancer

Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 Study

Impact of symptomatic skeletal events on health-care resource utilization and quality of life among patients with castration-resistant prostate cancer and bone metastases

Autoantibody Signatures in Prostate Cancer

Pharmacokinetic (PK) analysis of concurrent administration of enzalutamide (enza) and crizotinib (crizo) in patients with metastatic castration resistant prostate cancer (CRPC)

Gene expression correlates of clinical prostate cancer behavior

Patient-Reported Impotence and Incontinence After Nerve-Sparing Radical Prostatectomy

Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer

Imaging, procedural and clinical variables associated with tumor yield on bone biopsy in metastatic castration-resistant prostate cancer

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

Outcomes of prechemotherapy (pCRx) abiraterone acetate (AA) or enzalutamide (E) for metastatic castration-resistant prostate cancer (mCRPC) after ADT + Docetaxel (D) or ADT alone for metastatic hormone sensitive prostate cancer (mHSPC) in a multi-institution hospital-based registry

Predictors of duration of abiraterone acetate in men with castration-resistant prostate cancer

Recent progress in management of advanced prostate cancer

Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T

Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet

Prostate Intraepithelial Neoplasia Induced by Prostate Restricted Akt Activation: The MPAKT Model

Patient-reported symptoms after primary therapy for early prostate cancer: results of a prospective cohort study

Imaging yield from 133 consecutive patients with prostate cancer and low trigger PSA from a single institution

Percent Positive Biopsy Cores and the Risk of Death from Prostate Cancer in Men Treated with Radiation and Androgen Deprivation Therapy

Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer

Suchergebnisse filtern